Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDIT NASDAQ:FMTX NASDAQ:PCVX NASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$3.24+0.3%$2.77$0.91▼$3.80$291.34M2.162.12 million shs2.40 million shsFMTXForma Therapeutics$20.01$20.00$4.95▼$20.68$957.54M-0.94847,595 shs1 shsPCVXVaxcyte$33.98+5.7%$32.52$27.66▼$118.62$4.41B1.041.84 million shs2.00 million shsSRRKScholar Rock$38.75+12.4%$34.12$6.76▼$46.98$3.72B0.362.59 million shs4.39 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine0.00%+14.49%+22.26%+42.11%-4.42%FMTXForma Therapeutics0.00%0.00%0.00%0.00%0.00%PCVXVaxcyte0.00%+7.02%+10.43%+4.30%-70.05%SRRKScholar Rock0.00%+25.65%+16.44%+8.21%+350.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$3.24+0.3%$2.77$0.91▼$3.80$291.34M2.162.12 million shs2.40 million shsFMTXForma Therapeutics$20.01$20.00$4.95▼$20.68$957.54M-0.94847,595 shs1 shsPCVXVaxcyte$33.98+5.7%$32.52$27.66▼$118.62$4.41B1.041.84 million shs2.00 million shsSRRKScholar Rock$38.75+12.4%$34.12$6.76▼$46.98$3.72B0.362.59 million shs4.39 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine0.00%+14.49%+22.26%+42.11%-4.42%FMTXForma Therapeutics0.00%0.00%0.00%0.00%0.00%PCVXVaxcyte0.00%+7.02%+10.43%+4.30%-70.05%SRRKScholar Rock0.00%+25.65%+16.44%+8.21%+350.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.23Hold$5.1057.41% UpsideFMTXForma Therapeutics 0.00N/AN/AN/APCVXVaxcyte 3.00Buy$106.25212.68% UpsideSRRKScholar Rock 3.23Buy$46.4019.74% UpsideCurrent Analyst Ratings BreakdownLatest PCVX, FMTX, SRRK, and EDIT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/24/2025SRRKScholar RockPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$52.00 ➝ $51.009/24/2025SRRKScholar RockBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$45.00 ➝ $44.009/23/2025SRRKScholar RockHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $44.009/17/2025SRRKScholar RockBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$45.009/16/2025SRRKScholar RockBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$45.009/15/2025SRRKScholar RockLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/15/2025SRRKScholar RockLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$51.009/12/2025PCVXVaxcyteThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$38.009/5/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/3/2025EDITEditas MedicineWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$3.00 ➝ $4.008/21/2025SRRKScholar RockJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.00(Data available from 9/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$32.31M9.02N/AN/A$1.63 per share1.99FMTXForma Therapeutics$100.56M9.52N/AN/A$10.51 per share1.90PCVXVaxcyteN/AN/AN/AN/A$26.52 per shareN/ASRRKScholar Rock$33.19M112.23N/AN/A$3.94 per share9.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$237.09M-$2.85N/AN/AN/A-608.88%-200.25%-68.57%11/3/2025 (Estimated)FMTXForma Therapeutics-$172.96M-$4.00N/AN/AN/AN/A-39.68%-35.33%N/APCVXVaxcyte-$463.93M-$4.11N/AN/AN/AN/A-16.85%-15.92%11/4/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.91N/AN/AN/AN/A-127.11%-90.09%11/11/2025 (Estimated)Latest PCVX, FMTX, SRRK, and EDIT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025EDITEditas Medicine-$0.41-$0.63-$0.22-$0.63$1.81 million$3.58 million8/6/2025Q2 2025PCVXVaxcyte-$1.12-$1.22-$0.10-$1.22N/AN/A8/6/2025Q2 2025SRRKScholar Rock-$0.66-$0.98-$0.32-$0.98$0.11 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AFMTXForma TherapeuticsN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A2.772.77FMTXForma TherapeuticsN/A12.7412.74PCVXVaxcyteN/A11.1111.11SRRKScholar Rock0.216.336.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%FMTXForma Therapeutics87.39%PCVXVaxcyte96.78%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine1.90%FMTXForma Therapeutics5.79%PCVXVaxcyte3.10%SRRKScholar Rock13.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23089.92 million88.21 millionOptionableFMTXForma Therapeutics16647.85 million45.08 millionNot OptionablePCVXVaxcyte160129.82 million125.80 millionOptionableSRRKScholar Rock14096.13 million83.34 millionOptionablePCVX, FMTX, SRRK, and EDIT HeadlinesRecent News About These CompaniesLeerink Partnrs Raises Earnings Estimates for Scholar RockSeptember 28 at 2:15 AM | americanbankingnews.comScholar Rock FY2025 EPS Forecast Reduced by HC WainwrightSeptember 27 at 2:31 AM | americanbankingnews.comInvestors Purchase High Volume of Scholar Rock Put Options (NASDAQ:SRRK)September 27 at 2:15 AM | americanbankingnews.comLeerink Partnrs Predicts Increased Earnings for Scholar RockSeptember 26 at 7:18 AM | marketbeat.comWedbush Has Pessimistic View of Scholar Rock FY2025 EarningsSeptember 26 at 2:25 AM | americanbankingnews.comBarclays Has Lowered Expectations for Scholar Rock (NASDAQ:SRRK) Stock PriceSeptember 26 at 2:09 AM | americanbankingnews.comScholar Rock Sees Unusually Large Options Volume (NASDAQ:SRRK)September 25 at 11:21 AM | marketbeat.comFY2025 EPS Estimates for Scholar Rock Lowered by AnalystSeptember 25 at 7:50 AM | marketbeat.comWhat is Wedbush's Estimate for Scholar Rock FY2025 Earnings?September 25 at 7:50 AM | marketbeat.comScholar Rock (NASDAQ:SRRK) Insider Mo Qatanani Sells 3,353 SharesSeptember 25 at 6:06 AM | insidertrades.comScholar Rock (NASDAQ:SRRK) Shares Gap Down After Analyst DowngradeSeptember 25 at 2:15 AM | americanbankingnews.comScholar Rock price target lowered to $44 from $45 at BarclaysSeptember 24, 2025 | msn.comScholar Rock (NASDAQ:SRRK) Insider Sells $102,836.51 in StockSeptember 24, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Price Target Lowered to $44.00 at BarclaysSeptember 24, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Given New $44.00 Price Target at HC WainwrightSeptember 24, 2025 | americanbankingnews.comScholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility IssuesSeptember 23, 2025 | msn.comScholar Rock stock falls after FDA issues response letter for SMA drugSeptember 23, 2025 | ca.investing.comFDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent ...September 23, 2025 | finance.yahoo.comUS FDA declines to approve Scholar Rock's muscle weakness drug; shares fallSeptember 23, 2025 | msn.comScholar Rock: Despite CRL, This Is A Strong Buy With Apitegromab ExpansionsSeptember 23, 2025 | seekingalpha.comScholar Rock (NASDAQ:SRRK) Shares Gap Down Following Analyst DowngradeSeptember 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCVX, FMTX, SRRK, and EDIT Company DescriptionsEditas Medicine NASDAQ:EDIT$3.24 +0.01 (+0.31%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$3.24 -0.01 (-0.15%) As of 09/26/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Forma Therapeutics NASDAQ:FMTXForma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.Vaxcyte NASDAQ:PCVX$33.98 +1.84 (+5.72%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$34.44 +0.46 (+1.35%) As of 09/26/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Scholar Rock NASDAQ:SRRK$38.75 +4.26 (+12.35%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$38.88 +0.13 (+0.32%) As of 09/26/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/22 - 09/26 Get Exposure to Millennials' Purchasing Power With This ETF Beam Global Gets Buy Rating With 101% Upside Potential Institutional Buying Sets a High Floor for Microsoft Stock High-Momentum ETFs to Mine for Gold, Silver, and Bitcoin It's a Good Time to Build a Position in KB Home Alphabet: Time to Take Profits, Buy, or Wait for a Pullback? NuScale, Rocket Lab Face Heavy Insider Selling After Surges Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
